Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
Geburtshilfe Frauenheilkd 2003; 63(3): R41-R64
DOI: 10.1055/s-2004-817985
DOI: 10.1055/s-2004-817985
GebFra-Refresher
Georg Thieme Verlag Stuttgart · New York
Der klinische Einsatz von GnRH-Analoga in der Gynäkologie
Further Information
Publication History
Publication Date:
02 April 2003 (online)
![](https://www.thieme-connect.de/media/gebfra/200303/lookinside/thumbnails/10.1055-s-2004-817985-1.jpg)
Die Herstellung synthetischer Gonadotropin-Releasing-Hormon-(GnRH-) Agonisten
GnRH-Agonisten steigern kurz die Gonadotropinauschüttung, bevor Hormonsynthese und -ausschüttung abfallen (desensitization). |
GnRH-Antagonisten blockieren ohne Verzögerung die Gonadotropinausschüttung. |
Hauptindikationen für GnRH-Analoga: hormonabhängige gutartige Tumoren, maligne Tumoren, COH. |
Literatur
- 1 Kiesel L. Molecular mechanisms of gonadotrophin releasing hormone-stimulated gonadotrophin secretion. Hum Reprod. 1993; 8 (Suppl. 2) 23-28
- 2 Naor Z, Shacham S, Harris D, Seger R, Reiss N. Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross talk of calcium, proteinkinase C (PKC) and arachidonic acid. Cell Molec Neurobiol. 1996; 15 527-544
- 3 Kiesel L, Kaufmann M, Haeseler P, Klinga K, von HoIst T, Schmidt W, Runnebaum B. GnRH-receptors in primary human breast cancer. Geburtsh Frauenheilk. 1988; 48 420-424
- 4 Latouche J, Crumeyrolle-Arias M, Jordan D. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology. 1989; 125 1739-1741
- 5 Dong K W, Marcelin K, Hsu M I, Hoffman G, Roberts J L. Expression of gonadotropin-releasing hormone gene in human uterine endometrial tissue. Mol Hum Reprod. 1998; 4 893-898
- 6 Emons G, Pahwa G S, Brack C, Sturm R, Oberheuser F, Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol. 1989; 25 215-221
- 7 Lin Y, Kahn J A, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotropin-releasing hormone agonist or gonadotropin-releasing hormone antagonist?. Hum Reprod. 1999; 14 885-888
- 8 Duijkers I J, Klipping C, Willemsen W N, Krone D, Schneider E, Niebch G, Hermann R. Single and multiple dose pharmakokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod. 1998; 13 2392-2398
- 9 Barbieri R L. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992; 166 740-745
- 10 Surrey E S. Steridal or nonsteroidal “add-back” therapy: extending safety and efficacy of gonadotropin-releasing hormone agonist in the gynecologic patient. Fertil Steril. 1995; 64 673-685
- 11 Kiesel L, Schweppe K W, Sillem M, Siebzehnrubl E. Should add-back therapy for endometriosis be deferred for optimal results?. Br J Obstet Gynaecol. 1996; 103 (Suppl 14) 15-17
- 12 Franke H R, van de Weijer P H, Pennings T M, van der Mooren M J. Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000; 74 534-539
- 13 Stewart E A, Friedman A J. Steroidal treatment of myomas: preoperative and longterm medical therapy. Semin Reprod Endocrinol. 1992; 10 344-357
- 14 Friedman A J, Lobel S M, Rein M S, Barbieri R L. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990; 163 1114-1119
- 15 Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998; 30 295-305
- 16 Pierce S J, Gazvani M R, Farquharson R G. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril. 2000; 74 964-968
- 17 Bergquist C. Effects of nafarelin vs. danazol on lipids and Kalzium metabolism. Am J Obstet Gynecol. 1990; 162 589-591
- 18 Tonini G, Marinoni S, Forleo V, Rustica M. Local reactions to luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1995; 126 159
- 19 Jay N, Mansfield M J, Blizzard R M, Crowley Jr W F, Schoenfeld D, Rhubin L, Boepple P A. Ovulation and menstrual function of adolescent girls with central prcocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 1992; 75 890-894
- 20 Kiesel L, Bertges K, von Holst T R, Runnebaum B. Treatment of endometriosis. Arch Gynecol Obstet. 1989; 245 937-940
- 21 Lemay A, Maheux R, Huot C, Blanchet J, Faure N. Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis. Am J Obstet Gynecol. 1988; 158 233-236
- 22 Prentice A, Deary A J, Goldbeck-Wood S, Farquhar C, Smith S K. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Sys Rev 2000; 2: CD000346.
- 23 Hughes E, Fedorkow D, Collins J, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Sys Rev 2000; 2: CD000155.
- 24 Thomas E J. The relevance of asymptomatic endometriosis. Hum Reprod. 1996; 11 (Suppl. 3) 103-109
- 25 Parazzini F. Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi. Hum Reprod. 1999; 14 1332-1334
- 26 Fedele L, Bianchi S, Zanconato G, Tozzi L, Raffaelli R. Gonadotropin-releasing hormone agonist treatment for endometriosis of the rectovaginal septum. Am J Obstet Gynecol 2000. 2000; 183 1462-1467
- 27 Schindler A E, Foertig P, Kienle E, Regidor P A. Early treatment of endometriosis with GnRH-agonists: impact on time to recurrence. Eur J Obstet Gynecol Reprod Biol,. 2000; 93 123-125
- 28 Letterie G S, Coddington C C, Winkel C A, Shawker T H, Loriaux D L, Collins L R. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: long-term Follow-up. Fertil Steril. 1989; 51 951-956
- 29 Cheng Y M, Chou C Y, Huang S C, Lin H C. Oestrogen deficiency causes DANN damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists. Br J Obstet Gynecol. 2001; 108 95-102
- 30 Gokdeniz R, Ozen S, Mizrak B, Bazoglu N. GnRH agonist decreases endothelial nitric oxide synthase (eNOS) expression in leiomyoma. Int J Gynecol Obstet. 2000; 70 347-352
- 31 Kawaguchi D, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989; 160 637-641
- 32 Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P, Norgren A, Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998; 83 4092-4096
- 33 Maruo T, Matsuo H, Smoto T, Shimomura Y, Kurachi O, Gao Z, Wang Y, Spitz I M, Johansson E. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000; 65 585-592
- 34 Friedman A J, Barbieri R L, Doubilet P M, Fine C, Schiff I. A randomized, double-blind trial of a gonadotropin releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril. 1988; 49 404-409
- 35 Stovall T G, Ling F W, Henry L C, Woodruff M R. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol. 1991; 164 1420-1423
- 36 Felberbaum R E, Germer U, Ludwig M, Riethmuller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod. 1998; 13 1660-1668
- 37 Sculpher M, Thompson E, Brown J, Garry R. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents. Br J Obstet Gynecol. 2000; 107 340-346
- 38 Sowter Singla Lethaby M CAAA. Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Cochrane Database Sys Rev 2000; 2: CD001124.
- 39 Weeks A D, Duffy S R, Walker J J. A double blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. Br J Obstet Gynecol. 2000; 107 323-328
- 40 Kurjac A, Kupesic S. Ovarian senescence and its significance on uterine and ovarian perfusion. Fertil Steril. 1995; 64 532-537
- 41 Grimbizis G, Tsalikis T, Tzioufa V, Kasapis M, Mantalenakis S. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod. 1999; 14 479-484
- 42 Early Breast Cancer Trialists' Collaborative Group . Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet. 1992; 399 1-15
- 43 Paradiso A, Pezzetta A, Cellamare G, Schittulli F, Marzullo F, Reshkin S J. GnRH receptors in human breast cancer and its contiguous not-involved breast tissue. J Endocrinol Invest. 2000; 23 90-96
- 44 Jonat W, Kaufmann M, Blamey R W, Howell A, Collins J P, Coates A, Eiermann W, Janicke F, Njordenskold B, Forbes J F, Kolvenbag G JCM. A randomized study to compare the effect of the luteinizing hormone-releasing hormone (LH-RH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995; 31 A 137-142
- 45 Klijn J G, Beex L V, Mauriac L, van Zijl J A, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cacner: a randomized study. J Natl Cancer Inst. 2000; 92 903-911
- 46 Roche H H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, Chapelle-Marcillac I, Bardonnet M. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients with positive hormone-receptor. Proc Am Soc Clin Oncol 2000: abstract 279
- 47 Kim J H, Park D C, Kim J W, Choi Y K, Lew Y O, Kim D H, Jung J K, Lim Y A, Namkoong S E. Antitumor effects of GnRH agonist in epithelial ovarian cancer. Gynecol Oncol. 1999; 74 170-180
- 48 Emons G, Schally A V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod. 1994; 7 1364-1379
- 49 Wang P H, Chao H T, Lee W L. Use of a long-acting gonadotropin-releasing hormone agonist for treatment of steroid cell tumors of the ovary. Fertil Steril. 1998; 69 353-355
- 50 Emons G, Schulz K D. Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res. 2000; 153 83-94
- 51 Hofstra L S, Mourits M J, de Vries E G, Mulder N H, Willemse P H. Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res. 1999; 19 3627-3630
- 52 Chatzaki E, Bax C M, Eidne K A, Anderson L, Grudzinskas J G, Gallagher C J. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res. 1996; 56 2059-2065
- 53 Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Fraussen E, Rochie K. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997; 64 126-129
- 54 Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist parallel to chemotherapy. Human Reproduction. 1996; 11 1620-1626
- 55 Anderson R A, Kinniburgh D, Baird D T. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-viitro fertilization prior to cancer treatment. Hum Reprod. 1999; 14 2665-2668
- 56 Porter R N, Smith W, Craft I L, Abdulwahid N A, Jacobs H S. Induction of ovulation for in-vitro fertilization using Buserelin and gonadotropins. Lancet. 1984; 2 1284-1285
- 57 Garcia J E, Padilla S L, Bayati J, Baramki T A. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. Fertil Steril. 1990; 53 302-305
- 58 Tan S L, Kingsland C, Campbell S, Mills C, Bradfield J, Alexander N, Yovich J, Jacobs H S. The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in-vitro fertilization. Fertil Steril. 1992; 57 810-814
- 59 Dada T, Salha O, Baillie H S, Sharma V. A comparison of three gonadotropin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study. Hum Reprod. 1999; 14 288-293
- 60 MacDougall M J, Tan S L, Jacobs J S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 1992; 7 597-600
- 61 Kim C H, Cho Y K, Mok J E. Simplified ultralong protocol of gonadotrophin releasing hormone agonist for ovulation induction with intrauterine insemination in patients with endometriosis. Hum Reprod. 1996; 11 398-402
- 62 Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitation in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Sys Rev 2000; 1: CD001299.
- 63 Ranieri D M, Phophong P, Khadum I, Meo F, Davis C, Serhal P. Simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue (F-G-test) allows effective drug regimen selection for IVF. Hum Reprod. 2001; 16 673-675
- 64 Check J H, Nazari A, Barnea E R, Weiss W, Vetter B H. The efficacy of short-term gonadotrophin-releasing hormone agonists versus human chorionic gonadotrophin to enable oocyte release in gonadotrophin stimulated cycles. Hum Reprod. 1993; 8 568-571
- 65 Hughes E, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphen-resistant polycystic ovarian syndrome. Cochrane Database Sys Rev 2000; 2: CD000097.
- 66 Ludwig M, Felberbaum E R, Diedrich K, Hamm W, Riethmueller-Winzen H, Ulrich H. Cetrorelix im Mehrfachgabe-Protokoll zur ovariellen Stimulation bei der IVF. Reproduktionsmedizin. 2000; 16 390-399
- 67 Klingmuller D, Diedrich K, Sommer L. Effects of the GnRH antagonist Cetrorelix in normal women. Gynecol Endocrinol. 1993; 7 2
- 68 Christin-Maitre S, Olivennes F, Dubourdieu S, Chabbert-Buffet N, Charbonnel B, Frydman R P, Bouchard P. Effect of GnRH antaggonist during the LH surge in normal, women and during controlled ovarian hyperstimulation. Clin Endocrinol. 2000; 52 721-726
- 69 Olivennes F, Belaisch-Allart J, Emperaire J-C, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn J R, Bouchard P, Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril. 2000; 73 314-320
- 70 Mannaerts B, Gordon K. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum Reprod. 2000; 15 1882-1883
- 71 Hernandez E R. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod. 2000; 15 1211-1216
- 72 Mehta R H, Anand Kumar T C. Can GnRH agonists act directly on the ovary and contribute to cyst formation. Hum Reprod. 2000; 15 505-507
- 73 von Minckwitz G, Kaufmann M. New endocrine approaches in the treatment of brest cancer. Biomed Pharmacother. 1998; 52 122-132
- 74 Kaufmann M, Jonat W, Kleeberg U, Eiermann W. Goserelin, a depot GnRH-agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. J Clin Oncol. 1989; 7 1113-1119
- 75 Kaufmann M, von Minckwitz G. The emerging role of hormonal ablation as adjuvant therapy in node positive and node negative pre-/perimenopausal patients. The Breast. 2001; 10 (Suppl. ) 123-129
- 76 Jakesz R, Hausmaninger H, Samonigg H. Comparison of adjuvant therapy with tamoxifen and goserelin versus CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of ABCSG trial 5. Proc Am Soc Clin Oncol. 1999; 18 67a
- 77 Boccardo F, Rubagotti A, Amoroso D. Cyclophosphamide, methotrexate and fluoruracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: result of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000; 18 2718-2727